Celcuity Q2 FY26 net loss widens to $78.9 million; operating expenses climb to $66.1 million

• Celcuity posted a GAAP net loss of $78.9 million, or $1.44 a share, widening from $45.3 million a year earlier.
• Total operating expenses climbed to $66.1 million from $44 million, as SG&A jumped to $35 million from $7.6 million.
• R&D slipped to $31.1 million from $36.4 million, on lower VIKTORIA-1 trial costs and reduced license milestone expenses.
• Cash, cash equivalents and short-term investments rose to $754 million at quarter-end; net cash used in operations increased to $55.4 million.
• Gedatolisib branded REVTORPYK won FDA clearance on July 14; Celcuity targets a late third-quarter 2026 US launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131606PRIMZONEFULLFEED9809923) on August 13, 2026, and is solely responsible for the information contained therein.